Maria Sokratous

Dr. Maria Sokratous

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CMChrysa Marogianni
Chrysa Marogianni
MSMaria Sokratous
Maria Sokratous
Dardiotis EfthimiosDardiotis Efthimios
Dardiotis Efthimios
GHGeorgios Hadjigeorgiou
Georgios Hadjigeorgiou
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
GXGeorgia Xiromerisiou
Georgia Xiromerisiou
Parkinson’s disease (PD) is a neurodegenerative disorder, caused by, so far, unknown pathogenetic mechanisms. There is no doubt that pro-inflammatory immune-mediated mechanisms are pivotal to the pathogenicity and progression of the disease. In this review, we highlight the binary role of microglia activation in the pathophysiology of the disorder, both neuroprotective and neuromodulatory. We present how the expression of several cytokines implicated in dopaminergic neurons (DA) degeneration could be used as biomarkers for PD. Viral infections have been studied and correlated to the disease progression, usually operating as trigger factors for the inflammatory process. The gut–brain axis and the possible contribution of the peripheral bowel inflammation to neuronal death, mainly dopaminergic neurons, seems to be a main contributor of brain neuroinflammation. The role of the immune system has also been analyzed implicating a-synuclein in the activation of innate and adaptive immunity. We also discuss therapeutic approaches concerning PD and neuroinflammation, which have been studied in experimental and in vitro models and data stemming from epidemiological studies.

13 August 2021 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
LALiampas Andreas
Liampas Andreas
PNPanayiota Neophytou
Panayiota Neophytou
MSMaria Sokratous
Maria Sokratous
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
CIChristiana Ioannou
Christiana Ioannou
Panagiotis ZisPanagiotis Zis
Panagiotis Zis
Introduction Wheelchair users are at a high risk of experiencing non-neuropathic pain of musculoskeletal origin as a result of being wheelchair-bound. The aim of this systematic review was to establish the prevalence of musculoskeletal pain in wheelchair users that is attributable to wheelchair use, and to describe the different pain syndromes and discuss risk factors and management options. Methods After a systematic MEDLINE search, we identified 40 papers eligible for inclusion. Results The pooled prevalence of musculoskeletal pain at any location was 50% (95% CI 33–67%). The most common pain syndrome was shoulder pain (pooled prevalence 44%, 95% CI 36–52%). Wheelchair users were 5.8 times as likely to suffer from shoulder pain as controls (95% CI 2.7–12.2, p < 0.0001). Other pain syndromes included neck, elbow, wrist, hand and low back pain. Older age and increased duration of wheelchair use were the most significant determinants of pain in wheelchair users. Conclusions Musculoskeletal pain as a result of wheelchair use is very common amongst wheelchair users. Management of pain should follow national and international guidelines. Optimal adjustment of seating position may prevent pain, and is important to be taken into consideration.